Laman UtamaNBIX • NASDAQ
Neurocrine Biosciences Inc
$148.19
Selepas Waktu Dagangan:
$148.19
(0.00%)0.00
Tutup: 27 Jan, 4:03:18 PTG GMT-5 · USD · NASDAQ · Penafian
SahamSekuriti tersenarai ASIbu pejabat di AS
Tutup sebelumnya
$148.73
Julat hari
$147.20 - $151.53
Julat tahun
$110.95 - $157.98
Permodalan pasaran
15.00B USD
Bilangan Purata
1.00J
Nisbah P/E
39.68
Hasil dividen
-
Pertukaran utama
NASDAQ
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(USD)Sep 2024Perubahan T/T
Hasil
622.10J24.72%
Perbelanjaan pengendalian
234.30J14.74%
Pendapatan bersih
129.80J56.20%
Margin untung bersih
20.8625.21%
Pendapatan bagi setiap syer
1.8117.53%
EBITDA
191.30J30.40%
Kadar cukai berkesan
31.79%—
Jumlah aset
Jumlah liabiliti
(USD)Sep 2024Perubahan T/T
Pelaburan tunai dan jangka pendek
1.23B12.14%
Jumlah aset
3.54B24.11%
Jumlah liabiliti
816.10J-3.55%
Jumlah ekuiti
2.72B—
Syer tertunggak
101.25J—
Harga kepada buku
5.54—
Pulangan pada aset
13.51%—
Pulangan pada modal
15.91%—
Perubahan bersih dalam tunai
(USD)Sep 2024Perubahan T/T
Pendapatan bersih
129.80J56.20%
Tunai daripada operasi
158.00J-25.47%
Tunai daripada pelaburan
24.70J125.39%
Tunai daripada pembiayaan
26.40J40.43%
Perubahan bersih dalam tunai
209.40J56.85%
Aliran tunai bebas
-10.40J-106.50%
Perihal
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Diasaskan
1992
Pekerja
1,700
Cari
Kosongkan carian
Tutup carian
Apl Google
Menu utama